Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Increased TACE (Tumor necrosis factor-alpha±-converting enzyme; ADAM17) Activity Associates with Decreased CD62L Expression, Increased Soluble CD62L Plasma Levels and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP): Results from an ENEST1st Substudy

Sieghart Sopper, PhD, Satu Mustjoki, MD PhD, Angelica Loskog, PhD, Bjorn T. Gjertsen, MD PhD, Guenther A. Gastl, MD, Frank Giles, MDMB, Andreas Hochhaus, MD, Gert J. Ossenkoppele, MD PhD, Kimmo Porkka, MD PhD, Dominik Wolf, MD

Blood (2015) 126 (23): 4033.

https://doi.org/10.1182/blood.V126.23.4033.4033

Published: 2015

Journal Articles

Influence of Platelet and White Blood Cell Counts until Major Thrombosis: Analysis from a Patient Registry in Essential Thrombocythemia

Veronika Buxhofer-Ausch, Michael Steurer, Siegfried Sormann, Ernst Schloegel, Wolfgang Schimetta, Bettina Gisslinger, Reinhard Ruckser, Martin Schalling, MSc, Guenther A. Gastl, MD, Heinz Gisslinger, MD

Blood (2015) 126 (23): 2814.

https://doi.org/10.1182/blood.V126.23.2814.2814

Published: 2015

Journal Articles

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, MSc, Karin Strecker, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Pavla Kadlecova, PhD, Oleh Zagrijtschuk, MD, Christoph Klade, PhD, Richard Greil, MD

Blood (2014) 124 (21): 3177.

https://doi.org/10.1182/blood.V124.21.3177.3177

Published: 2014

Journal Articles

Methodological Characteristics Of Decision-Analytic Modeling Studies For The Treatment Of Multiple Myeloma

Ursula Rochau, MSc, Wolfgang Willenbacher, MD, Ella Willenbacher, MD, Beate Jahn, MSc, Vjollca Querimi, MD, Christina Kurzthaler, MSc, Martina Kluibenschaedl, MSc, Annette Conrads-Frank, MSc, Guenther A. Gastl, MD, Uwe Siebert, MD PhD MSc

Blood (2013) 122 (21): 2991.

https://doi.org/10.1182/blood.V122.21.2991.2991

Published: 2013

Journal Articles

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, Daniel Lechner, MD, Karin Strecker, MD, Alexander Egle, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Oleh Zahriychuk, MD, MSc, Christoph Klade, PhD, Richard Greil, MD

Blood (2013) 122 (21): 4046.

https://doi.org/10.1182/blood.V122.21.4046.4046

Published: 2013

Journal Articles

The G8 Screening Tool Detects Relevant Geriatric Impairments and Predicts Survival In Elderly Blood Cancer Patients

Reinhard Stauder, MD, MSc, Martina Mitrovic, MSc, Guenther A. Gastl, MD, Marije E Hamaker, MD, PhD

Blood (2013) 122 (21): 5209.

https://doi.org/10.1182/blood.V122.21.5209.5209

Published: 2013

Journal Articles

Analysis Of Molecular Responses and Chromosomal Aberrations In Patients With Polycythemia Vera Treated With Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) In The Peginvera Study

Nicole C.C. Them, M.Sc., Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Richard Greil, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Tiina Berg, Klaudia Bagienski, M.Sc., Oleh Zahriychuk, MD, Christoph Klade, PhD, Robert Kralovics, PhD

Blood (2013) 122 (21): 1589.

https://doi.org/10.1182/blood.V122.21.1589.1589

Published: 2013

Journal Articles

Fast Achievement Of a First Metabolic Complete Remission In a Lung Transtplanted Patient With Multiple Comorbidities and a CD30 Positive Anaplastic Large Cell Post-Transplant Lymphoproliferative Disorder (T-PTLD/ALCL) By Treatment With Brentuximab Vedotin Monotherapy

Ella Willenbacher, MD, Alfons Kreczy, MD, Christian Uprimny, MD, Brigitte Bucher, MD, Guenther A. Gastl, MD, Wolfgang Willenbacher, MD

Blood (2013) 122 (21): 5124.

https://doi.org/10.1182/blood.V122.21.5124.5124

Published: 2013

Journal Articles

Multicenter, Randomized, Phase III Study Comparing Imatinib (Glivec) Standard Dose (400 mg/d) with Imatinib High Dose Induction (800 mg/d) Followed by Imatinib Maintenance (400 mg/d) in Patients with Pretreated Ph + /BCR-ABL + CML in Chronic Phase - Results from the First Planned Interim Analysis (CELSG-CML 11 ISTAHIT Study).

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominik Fong, MD, Thomas Lion, MD, PhD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Emil Spasov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Atanas Stanchev, MD, Martin Kwakkelstein, MD, Hanno Ulmer, PhD, Guenther A. Gastl, MD

Blood (2007) 110 (11): 1048.

https://doi.org/10.1182/blood.V110.11.1048.1048

Published: 2007

Journal Articles

Stable RNAi-Mediated Knock-Down of P-Glycoprotein by a Transposon-Based Vector System Restores Imatinib Sensitivity.

Holger F. Rumpold, MD, Anna M. Wolf, MD, Guenther A. Gastl, MD, Eberhard Gunsilius, MD, Dominik G.F. Wolf, MD

Blood (2004) 104 (11): 2090.

https://doi.org/10.1182/blood.V104.11.2090.2090

Published: 2004

Journal Articles

Human Endothelial Cells Generated In Vitro from Circulating Progenitors Represent a Safe Tool for Targeting of Myocardial Tissue.

Ruth Koeck, Dominik G.F. Wolf, MD, Holger F. Rumpold, MD, Harald Ott, MD, Gerold Untergasser, MD, Martin Erdel, PhD, Paul Debagge, MD, Guenther A. Gastl, MD, Eberhard Gunslius, MD

Blood (2004) 104 (11): 4138.

https://doi.org/10.1182/blood.V104.11.4138.4138

Published: 2004

Journal Articles

Telomerase Activity and Telomere Length of CD4 + CD25 + Regulatory T-Cells under Conditions of In Vitro and In Vivo Expansion.

Dominik G.F. Wolf, MD, Anna M. Wolf, MD, Christian Koppelstaetter, MD, Holger F. Rumpold, MD, Gert Mayer, MD, Guenther A. Gastl, MD, Eberhard Gunsilius, MD, Herbert Tilg, MD

Blood (2004) 104 (11): 3857.

https://doi.org/10.1182/blood.V104.11.3857.3857

Published: 2004

Journal Articles

The Kinase Inhibitor Imatinib Mesylate Potently Inhibits TNF-α Production by Myeloid Cells and Prevents T-Cell-Mediated Hepatic Injury in Mice.

Anna M. Wolf, MD, Dominik G.F. Wolf, MD, Holger F. Rumpold, MD, Barabara Enrich, TA, Guenther A. Gastl, MD, Gunsilius Eberhard, MD, Herbert Tilg, MD

Blood (2004) 104 (11): 3438.

https://doi.org/10.1182/blood.V104.11.3438.3438

Published: 2004

NARROW

Influence of Platelet and White Blood Cell Counts until Major Thrombosis: Analysis from a Patient Registry in Essential Thrombocythemia

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Methodological Characteristics Of Decision-Analytic Modeling Studies For The Treatment Of Multiple Myeloma

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

The G8 Screening Tool Detects Relevant Geriatric Impairments and Predicts Survival In Elderly Blood Cancer Patients

Analysis Of Molecular Responses and Chromosomal Aberrations In Patients With Polycythemia Vera Treated With Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) In The Peginvera Study

Fast Achievement Of a First Metabolic Complete Remission In a Lung Transtplanted Patient With Multiple Comorbidities and a CD30 Positive Anaplastic Large Cell Post-Transplant Lymphoproliferative Disorder (T-PTLD/ALCL) By Treatment With Brentuximab Vedotin Monotherapy

Stable RNAi-Mediated Knock-Down of P-Glycoprotein by a Transposon-Based Vector System Restores Imatinib Sensitivity.

Human Endothelial Cells Generated In Vitro from Circulating Progenitors Represent a Safe Tool for Targeting of Myocardial Tissue.

Telomerase Activity and Telomere Length of CD4 + CD25 + Regulatory T-Cells under Conditions of In Vitro and In Vivo Expansion.

The Kinase Inhibitor Imatinib Mesylate Potently Inhibits TNF-α Production by Myeloid Cells and Prevents T-Cell-Mediated Hepatic Injury in Mice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only